Japan· JP-3919008S1025
マラリキシバット塩化物
A maralixibat chloride product containing マラリキシバット塩化物, registered in Japan by 武田薬品工業, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Maralixibat chloride is registered in 11 of 19 countries.
Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Maralixibat chloride · ATC A05AX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- マラリキシバット塩化物
- Manufacturer
- 武田薬品工業
- Country
- Japan (JP)
- ATC code
- A05AX04
- ATC class
- Maralixibat chloride
- Defined daily dose
- 28.5 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Maralixibat chloride in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLivmarli 10 mgMirum Pharmaceuticals International
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- IrelandLivmarli 10 mg tabletsMirum Pharmaceuticals International B.V.
- IcelandLivmarliMirum Pharmaceuticals International B.V.
- SwedenLivmarli 10 mg TablettMirum Pharmaceuticals International B.V.
- United StatesLivmarliMirum Pharmaceuticals Inc.
- CzechiaLIVMARLIMirum Pharmaceuticals International B.V., Amsterdam
- United KingdomLivmarli 10mg tabletsMirum Pharmaceuticals International BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Livmarli
- Liechtenstein · Livmarli
- Norway · Livmarli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/526ce062-1a85-45ef-a20f-85baa9dbc08c GET /v1/drugs/526ce062-1a85-45ef-a20f-85baa9dbc08c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１％３０ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3919008S1025",
"category": "内用薬",
"price_yen": 3888640.7,
"generic_name": "マラリキシバット塩化物",
"product_name_jp": null,
"therapeutic_class": "3919",
"transitional_expiry": null
}See everything about maralixibat chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.